Researchers are evaluating the P-CARE model, which integrates results from a blended genome-exome sequencing assay and family ...

The FDA cleared a second arm for enrollment in the trial after one NSCLC patient demonstrated a complete response to the non-boosted therapy.

The FDA released a much-anticipated draft guidance on how makers of rare disease genetic medicines can leverage a platform ...

Metabolon helped Kite study the link between metabolic signatures and the severity of neurological evens in samples from ...

The recommendation is based on results from 77 patients with pediatric low-grade glioma harboring a BRAF fusion or rearrangement or BRAF V600 mutation.

The trials in breast, lung, and colorectal cancer, supported by ARPA-H, will focus on guiding decisions across different lines of therapy using serial biopsies and tumor profiling.

GSK will pay the Chinese company $40 million upfront and up to $963 million in payments linked to development, regulatory, and commercial milestones.

In a study with three UK academic institutions, the platform agreed with MDx results 94 percent of the time in detecting ...

The gene therapy, which was acquired by Novartis in 2023, is also being tested in a separate Phase I/II trial of pediatric ...

Beam also unveiled a new platform-based approach to phenylketonuria treatments and a $500 million senior secured credit facility.

The firm is anticipating FDA approval for the bispecific antibody in HER2-positive gastroesophageal cancer this year and advancing the treatment in breast cancer studies.

The start of the Phase I trial for IDE034 triggers a milestone payment to Biocytogen, from which Ideaya acquired the program in 2024.